Ibrutinib is not an effective drug in primografts of TCF3-PBX1.

CONCLUSIONS: We conclude that ibrutinib is not the precision medicine of choice for TCF3-PBX1 positive BCP-ALL.
PMID: 32563910 [PubMed - as supplied by publisher]

Source: Translational Oncology - June 17, 2020 Category: Cancer & Oncology Authors: van de Ven C, Boeree A, Stalpers F, Zwaan CM, Den Boer ML Tags: Transl Oncol Source Type: research